Results 101 to 110 of about 20,079 (290)

New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What has been Investigated and What is in the Pipeline? [PDF]

, 2016
A wide range of support is available to help smokers to quit and aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion.
A Bisaga, A Jackson, A Kukkar, A Lenox-Smith, A Mann, A Parsons, A Sood, A Sood, A Verrotti, AE Evins, AH Glassman, AK Shinn, AM Joseph, AR Buchhalter, AS Rauhut, AV Prochazka, B Gaster, B Pasternak, B Spring, B Westenberger, BA Johnson, BF Grant, BM Kuehn, C Bullen, C Lerman, C Reavill, C Zona, C-Y Yeh, CA Martin, CD Cropp, CE Gartner, CF Koegelenberg, CL Bennett, CL DeVane, CL Strasinger, CT Bolliger, D Gonzales, D Hammond, D Kotz, D Kotz, D Kotz, D Mischoulon, D Moore, DA Baker, DA Baltieri, DA Revicki, Damian M. Cummings, DE Hilleman, DJ Romberger, DK Hatsukami, DK Hatsukami, DK Miller, DP Tashkin, E Beard, E Beard, E Beard, E Gere-Pászti, E Nowakowska, EA Finkelstein, EA Gilpin, EA McClure, EA Zimovetz, EC Westman, ED Levin, EG Guy, EH Cerny, EJ Jensen, EJ Mills, EJ Mills, EJ Wagena, Emma Beard, EW Tuan, F Wang, FT Filippidis, G Addolorato, G Chiara Di, G Cucchiaro, G Sutherland, GA Higgins, GM Keating, H Kitagawa, H McRobbie, H McRobbie, H Minami, H Myrick, H Pine-Abata, H-J Aubin, HM Schuller, I Berlin, J Balmford, J Brown, J Cornuz, J Foulds, J Foulds, J Kaper, J Kay, J Leaviss, J Ollivier, J Rose, J Shearer, J Shearer, J Yang, J-F Etter, J-G Gehricke, JA Dani, JE Henningfield, JE Henningfield, JE Rose, JE Rose, JE Sarginson, JF Rosenbaum, JM Ramon, JM Samet, JN Liberman, JO Ebbert, JO Ebbert, JR DiFranza, JR Hughes, JR Hughes, JS Ballon, JS Brown, JS Fowler, JW Lockner, K Bolin, K Demyttenaere, K Hara, K Ogita, K Silla, KA Holes-Lewis, KA Kasza, KA Perkins, KA Sacco, KC Waterman, KE Dunn, KE Farsalinos, KH Thomas, KP Garnock-Jones, KS Paudel, L Annemans, L Kozlowski, L Leggio, L Lima De, L Schmaal, L Shahab, L Shahab, LF Gaal Van, LH Ferry, Lion Shahab, LS Brose, LS Brose, LS Covey, M Farrell, M Harrison-Woolrych, M Hoogendoorn, M Khalifa, M Lader, M Mahmoudi, M McCarty, M Mugnaini, M Mula, M Neovius, M Ng, M Pravetoni, M Pravetoni, M Raw, M Raw, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Williams, M Wimbiscus, MA Jacobs, MA Russell, MA Russell, MC Fiore, ME Hadwiger, ME Jarvik, ME Jarvik, ME Mooney, ME Page, ME Thase, MFG Murphy, MG LeSage, MG LeSage, MH Ebell, MH Rapaport, ML Goniewicz, MM Moran, MY Bertram, N Benowitz, N Lindblom, N Walker, N Woolacott, NB Edwards, NF Woolacott, NL Benowitz, P Aveyard, P Farid, P Franks, P Gerrard, P Hajek, P Hajek, P Hajek, P Hajek, P Jha, P Maurer, P Popik, PH Hoogsteder, PH Silverstone, PM Bet, PM Cinciripini, PS Masand, R Benyamin, R Freedman, R Niaura, R Niaura, R Ray, R Richmond, R Shytle, R Taylor, R West, R West, R West, R West, R West, R West, R West, RA Brown, RA Schnoll, RA Schnoll, RB Barlow, RC Smith, RD Hurt, RD Hurt, RE Fahim, RF Yoshimura, RM Anthenelli, RM Pinder, Robert West, S Brimijoin, S Denford, S Greenland, S Leonard, S Shiffman, S Shiffman, S Shiffman, S Shiffman, S Singh, S Thornley, S Tonstad, S Tonstad, S Wanwimolruk, SA Ornish, SC Licata, SD Hall, SD Satoskar, SE Adkison, SH Villiers de, SL McElroy, SM Boekholdt, SM Holliday, SP Lakshmi, SS Hecht, Susan Michie, T Blondal, T Green, T Paparrigopoulos, T Raupach, TB Johnstone, TE Langley, TE Meyer, TJ Meine, TL Awtry, TM Luger, TR Franklin, U Eckstein-Ludwig, U Perngparn, V Butterweck, V Gligorijevic, V Klimek, V Varga, V Vengeliene, VS Kumar, W Berrettini, W Hao, W Pichayakorn, W Qiumei, WI Najm, WR Hiatt, X Shen, Y Buggy, Y Khazaal, Y-S Kim   +293 more
core   +1 more source

Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled Trial

Clinical pharmacology and therapy, 2020
It is unclear if genetic variants affect smoking cessation treatment response. This study tested whether variants in the cholinergic receptor nicotinic alpha 5 subunit (CHRNA5) predict response to smoking cessation medication by directly comparing the ...
Li-Shiun Chen, T. Baker, J. Miller, M. Bray, Nina Smock, Jingling Chen, Faith Stoneking, R. Culverhouse, N. Saccone, Christopher I. Amos, R. Carney, D. Jorenby, L. Bierut   +12 more
semanticscholar   +1 more source

Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis

Pharmacoepidemiology and Drug Safety, 2021
Varenicline is an effective treatment for smoking cessation. While clinical trials did not confirm a causal role, case reports suggested a possible link of varenicline with neuropsychiatric adverse drug events (NPAEs).
Yuanyuan Wang, J. Boven, J. Bos, C. Schuiling-Veninga, H. Boezen, B. Wilffert, E. Hak   +6 more
semanticscholar   +1 more source

Trends, timing, and predictors of alcohol use disorder treatment among US adult cancer survivors

Journal of Internal Medicine, EarlyView.
Abstract Background Little is known about the initiation of alcohol use disorder (AUD) treatments among cancer survivors, despite the unique harms that unhealthy alcohol use may have on this population. We assessed patterns, timing, and predictors of AUD treatment among cancer survivors.
Jyun‐Heng Lai, Anton L. V. Avanceña, Minh H. K. Nguyen, Corwin M. Zigler, Mary M. Velasquez, Christopher R. Frei, Michael Pignone   +6 more
wiley   +1 more source

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation

Health Technology Assessment, 2014
Background: Tobacco smoking is one of the leading causes of deaths worldwide. Nearly one-fifth of adults in the UK regularly smoke cigarettes. The ill-health associated with smoking costs the NHS over £3B every year.
Joanna Leaviss, William Sullivan, Shijie Ren, Emma Everson-Hock, Matt Stevenson, John W Stevens, Mark Strong, Anna Cantrell   +7 more
doaj   +1 more source

Nicotine dependence and neuropsychotic effects of varenicline

Безопасность и риск фармакотерапии, 2018
Varenicline is a partial agonist of nicotinic acetylcholine receptors for the therapy of nicotine addiction. The efficacy and safety of the use of varenicline in the treatment of nicotine dependence have been demonstrated in clinical trial EAGLES.
T. M. Bukatina, A. S. Kazakov, R. N. Alyautdin, T. V. Romanova, I. I. Snegireva   +4 more
doaj   +1 more source

Comparative Effectiveness of Smoking Cessation Medications: A National Prospective Cohort From Taiwan. [PDF]

PLoS ONE, 2016
Relative effectiveness of smoking cessation medications-varenicline, bupropion and nicotine replacement therapy (NRT)-remains unclear among smokers in real-world settings.
Po-Yin Chang, Po-Ching Lo, Hui-Chin Chang, Kuang-Chieh Hsueh, Yi-Wen Tsai   +4 more
doaj   +1 more source

Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation [PDF]

, 2013
PMCID: PMC3602285This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided ...
Bullen, C, Howe, C, Laugesen, M, McRobbie, H, Parag, V, Walker, N, Williman, J   +6 more
core   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Does e‐cigarette nicotine strength influence substitution for combustible cigarettes?

Journal of the Experimental Analysis of Behavior, Volume 124, Issue 3, November 2025.
Abstract Using the Experimental Tobacco Marketplace, we examined the effects of e‐liquid freebase nicotine strength (3–24 mg/mL) and e‐liquid price (US$0.25–$1.00/mL) on behavioral economic substitution for cigarettes in dual cigarette/e‐cigarette (n = 41) and exclusive cigarette (n = 40) users.
Jeffrey S. Stein, Allison N. Tegge, Jeremiah M. Brown, Kelsey M. Curran, Warren K. Bickel   +4 more
wiley   +1 more source